Qsemble Capital Management LP Has $773,000 Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Qsemble Capital Management LP lessened its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 9.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,848 shares of the biotechnology company’s stock after selling 960 shares during the quarter. Qsemble Capital Management LP’s holdings in BioMarin Pharmaceutical were worth $773,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Lindbrook Capital LLC raised its stake in BioMarin Pharmaceutical by 259.8% in the fourth quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 278 shares during the period. Benjamin F. Edwards & Company Inc. boosted its position in BioMarin Pharmaceutical by 135.3% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 249 shares during the period. Jones Financial Companies Lllp acquired a new stake in shares of BioMarin Pharmaceutical during the 4th quarter worth about $43,000. First Horizon Advisors Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 33.3% during the 4th quarter. First Horizon Advisors Inc. now owns 576 shares of the biotechnology company’s stock worth $56,000 after buying an additional 144 shares during the period. Finally, Allworth Financial LP raised its holdings in BioMarin Pharmaceutical by 54.9% in the 4th quarter. Allworth Financial LP now owns 604 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 214 shares during the period. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Baird R W downgraded BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 17th. Canaccord Genuity Group lowered their price objective on BioMarin Pharmaceutical from $91.00 to $89.00 and set a “hold” rating on the stock in a research report on Friday, April 26th. Evercore ISI started coverage on shares of BioMarin Pharmaceutical in a research report on Tuesday, May 14th. They set an “outperform” rating and a $113.00 price target on the stock. Citigroup dropped their price target on shares of BioMarin Pharmaceutical from $94.00 to $91.00 and set a “neutral” rating for the company in a research report on Thursday, April 25th. Finally, Robert W. Baird downgraded BioMarin Pharmaceutical from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $104.00 to $72.00 in a research report on Friday, May 17th. Nine research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $106.37.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, CFO Brian Mueller sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $75.19, for a total value of $375,950.00. Following the sale, the chief financial officer now owns 72,159 shares in the company, valued at approximately $5,425,635.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,850 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $85.01, for a total transaction of $157,268.50. Following the completion of the sale, the executive vice president now directly owns 56,157 shares in the company, valued at approximately $4,773,906.57. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brian Mueller sold 5,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $75.19, for a total value of $375,950.00. Following the completion of the transaction, the chief financial officer now directly owns 72,159 shares in the company, valued at $5,425,635.21. The disclosure for this sale can be found here. Insiders have sold 67,700 shares of company stock valued at $5,209,352 in the last ninety days. 1.85% of the stock is currently owned by insiders.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN traded down $1.29 during mid-day trading on Wednesday, hitting $84.60. 299,628 shares of the stock traded hands, compared to its average volume of 1,912,510. The company has a market cap of $16.06 billion, a PE ratio of 79.92, a price-to-earnings-growth ratio of 1.20 and a beta of 0.32. BioMarin Pharmaceutical Inc. has a twelve month low of $73.68 and a twelve month high of $99.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.74 and a quick ratio of 1.70. The firm has a 50 day simple moving average of $81.01 and a two-hundred day simple moving average of $86.10.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.12. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. The firm had revenue of $648.83 million for the quarter, compared to analyst estimates of $649.75 million. As a group, equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 1.99 EPS for the current fiscal year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.